Santhera Publishes Agenda for its Annual General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Ad hoc announcement pursuant to Art. 53 LR
Pratteln, Switzerland, June6, 2023 – Santhera Pharmaceuticals (SIX: SANN) today published the agenda for its Annual General Meeting (AGM), which will be held on June 27, 2023, at 10:00 CESTat Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.
The invitation to the Annual General Meeting with agenda items and explanations can be viewed on Santhera’s website at https://www.santhera.com/share-bondholder-meetings.
Selected agenda items
The Board of Directors proposes the re-election of Thomas Meier, PhD, and Philipp Gutzwiller as members of the BoD until the end of the AGM 2024. Additionally, Thomas Meier, PhD, is nominated for re-election as the Chairman of the BoD.
Patrick Vink, member of Santhera’s Board and Chairman of the Compensation Committee since 2017, decided not to stand for re-election. The BoD and Executive Committee sincerely thank Patrick for his dedication and valuable contributions and wish him all the best for the future.
The BoD nominates Bradley C. Meyer (as previously announced) and Otto Schwarz, PhD, for election to the Board:
Bradley C. Meyer has acted as a board observer of Santhera’s Board since March 2023. He is the founding partner of and a senior advisor at Ducera Partners and has vast experience in M&A, financial and other advisory services.
Otto Schwarz, PhD, is the former COO of Actelion Pharmaceuticals Ltd. Currently, he is Managing Director of Concentus Consulting, Switzerland. As of July 1, 2023, Otto Schwarz will act as an advisor to the management of Idorsia Pharmaceuticals Ltd, Santhera’s largest shareholder.
Subject to their (re-)election as Board members, the BoD proposes to the shareholders the re-election of Thomas Meier, PhD, and the election of Bradley C. Meyer as members of the Compensation Committee. It is intended that Bradley C. Meyer will be appointed as Chairman of the Compensation Committee.
Reverse Share Split
The BoD proposes a reverse share split in the ratio 10:1. Proposed is a 10-fold reduction of the number of shares accompanied by a 10-fold increase of the nominal value per share (from CHF 0.01 to CHF 0.10). This reverse split, if implemented, does not affect the market capitalization of Santhera, and the percentage interest in the Company's equity for the shareholder will essentially remain unchanged (except for cash compensation for fractional shares, i.e., those portions of existing shareholdings that are not divisible by ten).
The BoD anticipates potential benefits from the reverse share split, including heightened visibility and improved market perception of Santhera, as well as improved eligibility for institutional investors to invest in the Company.
Details on the reverse share split and explanations on its implementation are provided in the AGM invite and the Q&A which are both available on the Company’s website here.
Capital Range and Amendment to the Articles of Incorporation
This motion intends to introduce the instrument of a capital range as a replacement of the authorized share capital in accordance with the revised Swiss corporate law, which entered into force this year.
The capital range provides the BoD with a flexible instrument enabling it, among other things, to decrease the Company’s share capital or to issue, without delay, new shares within a certain range for financing purposes at a moment favorable to the Company.
- Approval of the Annual Report, Annual Financial Statements and the Consolidated Financial Statements 2022
- Appropriation of the Annual Result and Offset of Deficit
- Consultative Vote on the Compensation Report 2022
- Discharge of the Members of the Board of Directors and of the Executive Management from Liability for the Financial Year 2022
- Reverse Share Split
- Capital Range and Amendment to the Articles of Incorporation
- Conditional Capital for Financing Purposes and Amendment to the Articles of Incorporation
- Conditional Capital for Employee Participations and Amendment to the Articles of Incorporation
- Election and Re-Election of Members of the Board of Directors and Re-Election of the Chairman of the Board
- Election and Re-Election of the Members of the Compensation Committee
- Approval of the Compensation of the Members of the Board of Directors
- Approval of the Compensation of the Members of the Executive Management
- Re-election of the Statutory Auditors
- Re-election of the Independent Proxy
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license for all indications worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. For vamorolone in the treatment of DMD, Santhera has a new drug application (NDA) under review by the U.S. FDA, a marketing authorization application (MAA) under review by the European Medicines Agency (EMA) and an MAA submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
Disclaimer / Forward-looking statements
This document does not constitute an offer to subscribe for, buy or sell any of the securities mentioned herein or any other securities in any jurisdiction. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act.
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation: Repurchase of own shares on 26.09.202326.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 26 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 26.09.2023 Espoo, Finland – On 26 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL311,0543.56CEUX55,9623.57AQEU8,7573.55TQEX16,2273.57Total392,0003.56 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 202326.9.2023 19:56:38 CEST | Press release
Sunstone IV hf. Storhofdi 22-30, 110 Reykjavik, Iceland Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 2023 Consolidated condensed interim financial statements, for the six months ended June 30, 2023 of Sunstone IV hf. were approved at a Board of Directors meeting on 21 September 2023. The financial statements can be found on the Company’s website: https://www.mila.is/um-milu/fjarmal/sunstone-iv/ For more information please contact: Inga Helga Halldórudóttir Compliance officer Sunstone IV hf. firstname.lastname@example.org
Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub26.9.2023 18:20:01 CEST | Press release
Press Release Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub Nokia will join a new innovation hub that seeks to expand U.S. global leadership in microelectronics technical development.The program will help reduce U.S. reliance on foreign microelectronics and safeguard supply chain risks, while ensuring access to cutting edge semiconductors for the Department of Defense. 26 September 2023 Murray Hill, New Jersey – Nokia today announced that it is part of the Northeast Microelectronics Coalition (NEMC) Hub, a regional innovation hub led by the Massachusetts Technology Collaborative (MassTech). The NEMC Hub was recently awarded funding to advance the microelectronics needs of the U.S. Department of Defense (DoD) from the "Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act." The funding award will establish a total of eight Microelectronics Commons regional innovation hubs and Core Facilities distributed across the United St
ABC arbitrage : Continuation of liquidity contract of ABC ARBITRAGE26.9.2023 18:00:00 CEST | Press release
Continuation of liquidity contract of ABC ARBITRAGE ABC ARBITRAGE informs that it will continue the liquidity contract with Kepler Cheuvreux, adding the following additional resources: 80,000 in cash (transfer executed on 21 September 2023). As a reminder : • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account: - 51,410 shares - € 111,829.43 - Number of executions on buy side on semester: 783 - Number of executions on sell side on semester: 1,120 - Traded volume on buy side on semester: 125,924 shares for € 781,516.85 - Traded volume on sell side on semester: 115,527 shares for € 719,846.14 • the following resources appeared on the liquidity account when the activity started: - 28,440 shares - € 49,007.93 The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. Contacts : abc-arbitrage.com
ROBIT PLC: REPURCHASE OF OWN SHARES 26 SEPTEMBER 202326.9.2023 17:45:00 CEST | Press release
ROBIT PLC STOCK EXCHANGE RELEASE 26 SEPTEMBER 2023 AT 18.45 EEST ROBIT PLC: REPURCHASE OF OWN SHARES26 SEPTEMBER 2023 Robit PlcNasdaq Helsinki LtdDate26.9.2023Exchange transactionBUYShare trading codeROBITAmount, shares1765Average price / share, EUR1,453666Total cost, EUR2565,72 Robit Plc now holds a total of 17 479 shares including the shares repurchased on 26 September 2023. Detailed information concerning the repurchase is attached to this stock exchange release. On behalf of Robit Plc OP Corporate Bank Mikael Ahovuo Further information: Robit Plc Arto Halonen, Group CEO +358 40 028 0717 email@example.com Distribution: Nasdaq Helsinki Ltd Key media www.robitgroup.com Robit is the specialist focused on high quality drilling consumables for the mining and construction markets globally to help you drill even Further. Faster. Robit strives to be the world’s number one drilling consumables company. Through our proven, high-quality Top Hammer, Down the Hole and Geotechnical prod